Verisim Life, a San-Francisco based biotech startup, closed $5.2 million in a round of funding from firms including Intel Capital. Verisim acknowledges that the current process to bring a drug to clinical trials, let alone to market, involves a lot of animal testing that sees the majority of these drugs dismissed. As a result, the company has set out to develop disease-specific, machine learning based simulation models to test interactions between drugs and different animals' biological systems. This would dramatically decrease the time and cost required to take a drug to human clinical trials. This technology could one day be used to determine how a patient would react to a specific drug. As of now Verisim has just one published patent application, but this funding suggests there may be more applications that have been submitted, and provides financing for continued R&D.
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
View Patent Forecast®
Top Corporations
News and Insights
Data Visualization
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.